ArticleEuropean journal of microbiology & immunology2016
Targeting Antigens to Dec-205 on Dendritic Cells Induces Immune Protection in Experimental Colitis in Mice.
Article in European journal of microbiology & immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Myeloid-derived suppressor cells and pulmonary hypertension.Frontiers in immunology · 2023Review
- Targeted delivery of autoantigen to dendritic cells prevents development of spontaneous uveitis.Frontiers in immunology · 2023Article
- Cutting-Edge Delivery Systems and Adjuvants in Tolerogenic Vaccines: A Review.Pharmaceutics · 2022Review
- Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo.Antibodies (Basel, Switzerland) · 2022Review
- Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases.Frontiers in immunology · 2022Review
- Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity.International journal of molecular sciences · 2021Review
- Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance.Frontiers in immunology · 2021Review
- Circular RNA circSnx5 Controls Immunogenicity of Dendritic Cells through the miR-544/SOCS1 Axis and PU.1 Activity Regulation.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Qingchang Huashi granule ameliorates experimental colitis via restoring the dendritic cell-mediated Th17/Treg balance.BMC complementary medicine and therapies · 2020Article
- Targeting Dendritic Cells with Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases.Antibodies (Basel, Switzerland) · 2020Review
- Natural and Induced Tolerogenic Dendritic Cells.Journal of immunology (Baltimore, Md. : 1950) · 2020Review
- Advancing immunomodulation by in vivo antigen delivery to DEC-205 and other cell surface molecules using recombinant chimeric antibodies.International immunopharmacology · 2019Review
- Engineering Immune Tolerance with Biomaterials.Advanced healthcare materials · 2019Review
- Dendritic Cells As Inducers of Peripheral Tolerance.Trends in immunology · 2017Review
- Intestinal helminth infection drives carcinogenesis in colitis-associated colon cancer.PLoS pathogens · 2017Article
- Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endocytotic c-type lectin receptor DEC-205 is highly expressed on immature dendritic cells. In previous studies, it was shown that antigen-targeting to DEC-205 is a useful tool for the induction of antigen-specific Foxp3(+) regulatory T cells and thereby can prevent inflammatory processes. However, whether this approach is sufficient to mediate tolerance in mucosal tissues like the gut is unknown. In this study, we established a new mouse model in which the adoptive transfer of naive hemagglutinin (HA)-specific CD4(+)Foxp3(-) T cells into VILLIN-HA transgenic mice leads to severe colitis. To analyze if antigen-targeting to DEC-205 could protect against inflammation of the gut, VILLIN-HA transgenic mice were injected with an antibody-antigen complex consisting of the immunogenic HA110-120 peptide coupled to an α-DEC-205 antibody (DEC-HA) before adoptive T cell transfer. DEC-HA-treated mice showed significantly less signs of intestinal inflammation as was demonstrated by reduced loss of body weight and histopathology in the gut. Strikingly, abrogated intestinal inflammation was mediated via the conversion of naive HA-specific CD4(+)Foxp3(-) T cells into HA-specific CD4(+)Foxp3(+) regulatory T cells. In this study, we provide evidence that antigen-targeting to DEC-205 can be utilized for the induction of tolerance in mucosal organs that are confronted with large numbers of exogenous antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.